Clinical Trial Update: A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L) [Phase 2]

View source ↗

Summary

The SABRE-L study tested a combination of sunitinib, bevacizumab, carboplatin, and paclitaxel in advanced non-small cell lung cancer. The Phase 2 trial was term…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Avastin (bevacizumab)
• CARBOPLATIN (Carboplatin)
• Sutent (sunitinib)
• Taxol (paclitaxel)

Snippet

Sponsor: Genentech, Inc. | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2009-08-21